Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TXP1-Her2mAb
- Development stage
- Preclinical
- Lead developer
- Ossianix
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Parenteral
01
Overview
TXP1-Her2mAb is a preclinical-stage VNAR-antibody conjugate developed by Ossianix for the treatment of neuro-oncological conditions, including HER2-positive brain metastases. The therapeutic utilizes Ossianix's proprietary TXP1 VNAR (Variable New Antigen Receptor) single-domain antibody, which is derived from shark antibodies and serves as a blood-brain barrier (BBB) shuttle. This shuttle targets the transferrin receptor 1 (TfR1) to facilitate receptor-mediated transcytosis, effectively delivering a linked anti-HER2 monoclonal antibody across the BBB into the central nervous system. By overcoming the restrictive nature of the BBB, TXP1-Her2mAb aims to provide a targeted treatment option for HER2-expressing tumors within the brain. The program is currently undergoing in vivo testing in mouse models.
02
Targets
TFRC (Transferrin Receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on TXP1-Her2mAb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TXP1-Her2mAb.